NHLBI is issuing this Notice of Special Interest (NOSI) due to the urgent need for early phase clinical trials to evaluate new or existing interventions that may prevent or treat Coronavirus Disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). NHLBI seeks to leverage existing clinical trials expertise and, using NHLBI programs that are actively conducting Phase I-III clinical trials, to rapidly initiate and conduct Phase I-Phase I/II (bridging) clinical trials in patients at risk for SARS-CoV-2 infection and/or patients with COVID-19.

The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs at the National Cancer Institute (NCI) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for the development of prophylactic, therapeutic and diagnostic for Coronavirus Disease 2019 (COVID-19).

National Institute of Dental and Craniofacial Research (NIDCR) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on Coronavirus Disease 2019 (COVID-19). NIDCR will place a high priority on topics that would be of immediate and high impact to protect and ensure the safety of personnel and patients in dental practices. These topics include prevention of SARS-COV-2 transmission and improvements in the detection and diagnosis of COVID-19; as well as acquisition of a more robust understanding of SARS-CoV-2 pathogenesis.

National Institute of Dental and Craniofacial Research (NIDCR) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on Coronavirus Disease 2019 (COVID-19) conducted in the National Dental Practice-Based Research Network (PBRN). NIDCR will place a high priority on topics that would be of immediate and high impact to protect and ensure the safety of personnel and patients in dental practices, prevent SARS-CoV-2 transmission, and improve detection and diagnosis of COVID-19.

The National Center for Complementary and Integrative Health (NCCIH) announces the availability of funds for Administrative Supplements or Urgent Competitive Revisions to promote research on the effects of natural products alone or in combination with other complementary and integrative health approaches on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19).

NLM is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for innovative high-risk/high impact research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) in relation to NLM’s strategic goal of fostering data driven research.

Research Objectives

In order to rapidly improve our understanding of the infection of SARS-CoV-2 and of COVID-19, NLM is encouraging the submission of R21 applications to address the following research areas of interest:

The purpose of this Funding Opportunity Announcement (FOA) is to provide an expedited funding mechanism for research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19). NIAID is issuing this FOA in response to the declared public health emergency issued by the Secretary, HHS, for 2019 Novel Coronavirus (COVID-19).

The purpose of this Funding Opportunity Announcement (FOA) is to provide an expedited funding mechanism for research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19). NIAID is issuing this FOA in response to the declared public health emergency issued by the Secretary, HHS, for 2019 Novel Coronavirus (COVID-19).

Seeking applications for multicentered phase 2 and 3 randomized, controlled clinical trials of host-targeting strategies to prevent and treat SARS-CoV-2 disease. They are also soliciting applications from experienced Data and Clinical Coordinating Centers with an established network or consortium of Clinical Centers to serve as the Administrative Coordinating Center for the Network of Networks Platform.